INMB
Inmune Bio, Inc.
$1.26
-6.67%
$35.9M
No data for this timeframe.
Vol
Market Cap$35.9M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (90%)
Inst. Holders6 funds
Inst. Value$1.9M
Inst. Activity4 buys / 0 sells
SEC Reports4
Press Releases2
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. NV·CIK 0001711754·Prev Close $1.35
Recent Activity
Jun 2, 2026
SEC
INmune Bio reported statistically significant treatment effects on a white matter MRI biomarker (chi-separation) from th
8-K — Impact 7/10
May 7, 2026
SEC
INmune Bio reported Q1 2026 net loss narrowed to $5.4M from $9.7M YoY, but EPS of -$0.20 missed consensus of -$0.18 by 1
PRESS-RELEASE — Impact 4/10
May 5, 2026
SEC
Inmune Bio entered into an amended and restated Material Transfer and License Agreement with Anthony Nolan, securing lon
8-K — Impact 4/10
Inst.
MORGAN STANLEY — ADD
122,512 shares ($191.1K)
Inst.
WELLS FARGO & COMPANY/MN — ADD
24,857 shares ($38.8K)
Jun 2, 2026
other
INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial
<p align="center"><i>XPro1595 showed a highly significant treatment effect in the full mITT populati
Mar 30, 2026
Press
INmune Bio reported a net loss of $45.9 million for 2025, wider than the $42.1 million loss in 2024, driven by a $16.5 m
Impact 6/10
Mar 19, 2026
Press
INmune Bio highlighted positive biomarker-enriched Phase 2 MINDFuL trial results for XPro1595 in Alzheimer’s disease dur
Impact 7/10
Price Targets
$7.00
+455.6% upside
Strong Buy
Current $1.26
Low $4.00
Median $7.50
High $9.00
4 analysts
$4.00
$9.00
Analyst Ratings
2Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 11, 2026 | LUCID CAPITAL MARKETS | UPGRADE | Neutral → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.20 | $-0.23 — $-0.17 | 41% YoY | 2 |
| Next Q | $-0.17 | $-0.19 — $-0.14 | 31% YoY | 2 |
| Current FY | $-0.60 | $-0.82 — $-0.44 | 49% YoY | 3 |
| Next FY | $-0.53 ▲ +0.9% | $-0.55 — $-0.50 | 13% YoY | 2 |
Latest Reports
BULLISH
8-K
7/10
INmune Bio reported statistically significant treatment effects on a white matter MRI biomarker (chi-separation) from th
Jun 2, 2026
MIXED
PRESS-RELEASE
4/10
INmune Bio reported Q1 2026 net loss narrowed to $5.4M from $9.7M YoY, but EPS of -$0.20 missed consensus of -$0.18 by 1
May 7, 2026
MIXED
Press
6/10
INmune Bio reported a net loss of $45.9 million for 2025, wider than the $42.1 million loss in 2024, driven by a $16.5 m
Mar 30, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $1.5M | — |
| MORGAN STANLEY | $191.1K | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $78.4K | ADD |
| WELLS FARGO & COMPANY/MN | $38.8K | ADD |
| BANK OF AMERICA CORP | $28.9K | ADD |
6 institutional holders with $1.9M total value (1,188,105 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, CHARLES. Net buying activity: 4 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 957,846 | $1.5M | 80.6% | — |
| 2 | MORGAN STANLEY | 122,512 | $191.1K | 10.3% | ADD +61.8% |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 50,252 | $78.4K | 4.2% | ADD +25.4% |
| 4 | WELLS FARGO & COMPANY/MN | 24,857 | $38.8K | 2.1% | ADD +79.0% |
| 5 | BANK OF AMERICA CORP /DE/ | 18,541 | $28.9K | 1.6% | ADD +82.0% |
| 6 | FMR LLC | 14,097 | $22.0K | 1.2% | DOUBLED +344.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 75,710 | 122,512 | +61.8% | $191.1K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 13,887 | 24,857 | +79.0% | $38.8K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 10,187 | 18,541 | +82.0% | $28.9K | 2025-Q4 |
| FMR LLC | DOUBLED | 3,171 | 14,097 | +344.6% | $22.0K | 2025-Q4 |
| UBS Group AG | TRIM | 449,221 | 155,522 | -65.4% | $321.9K | 2025-Q3 |
| MORGAN STANLEY | TRIM | 102,738 | 75,710 | -26.3% | $156.7K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 9,683 | 13,887 | +43.4% | $28.7K | 2025-Q3 |
| FMR LLC | ADD | 2,510 | 3,171 | +26.3% | $6.6K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 35,591 | 0 | -100.0% | $0.00 | 2025-Q3 |
| UBS Group AG | DOUBLED | 137,315 | 449,221 | +227.1% | $1.0M | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 41,320 | 51,825 | +25.4% | $119.7K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 30,393 | 12,173 | -59.9% | $28.1K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 6,518 | 9,683 | +48.6% | $22.4K | 2025-Q2 |
| MORGAN STANLEY | TRIM | 155,126 | 84,464 | -45.6% | $659.7K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 66,384 | 30,563 | -54.0% | $238.7K | 2025-Q1 |
| FMR LLC | ADD | 1,629 | 2,973 | +82.5% | $23.2K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 185,800 | 0 | -100.0% | $0.00 | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 107,200 | 185,800 | +73.3% | $867.7K | 2024-Q4 |
| MORGAN STANLEY | ADD | 92,144 | 155,126 | +68.4% | $724.4K | 2024-Q4 |
| UBS Group AG | DOUBLED | 43,156 | 136,248 | +215.7% | $636.3K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 4,222 | 6,377 | +51.0% | $29.8K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 28,375 | 92,144 | +224.7% | $496.7K | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 33,990 | — | $183.2K | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
4 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 1 mixed, 1 neutral. Avg impact: 5.3/10.
BULLISH
8-K
7/10
INmune Bio reported statistically significant treatment effects on a white matter MRI biomarker (chi
Jun 2, 2026
MIXED
PRESS-RELEASE
4/10
INmune Bio reported Q1 2026 net loss narrowed to $5.4M from $9.7M YoY, but EPS of -$0.20 missed cons
May 7, 2026
NEUTRAL
8-K
4/10
Inmune Bio entered into an amended and restated Material Transfer and License Agreement with Anthony
May 5, 2026
BEARISH
PRESS-RELEASE
6/10
INmune Bio reported Q4 2025 EPS of -$0.20, missing the consensus estimate of -$0.18 by 11.1%. The pr
Apr 30, 2026
Current analyst consensus: Strong Buy (90% buy). Based on 10 analysts: 2 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$7.00 mean target
+455.6% upside
Strong Buy (1.25)
$4.00 Low
$9.00 High
| Metric | Value |
|---|---|
| Current Price | $1.26 |
| Target Low | $4.00 |
| Target Mean | $7.00 |
| Target Median | $7.50 |
| Target High | $9.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (1.25) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.20 | $-0.23 | $-0.17 | 41.3% | — | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Next Q 2026-09-30 |
$-0.17 | $-0.19 | $-0.14 | 31.3% | — | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Current FY 2026-12-31 |
$-0.60 | $-0.82 | $-0.44 | 49.2% | — | 2↑ 0↓ | $0.0B | -100.0% | 3 |
| Next FY 2027-12-31 |
$-0.53 | $-0.55 | $-0.50 | 13.0% | +0.9% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.200 | |
| 7d ago | $-0.200 | |
| 30d ago | $0.000 | -0.200 |
| 60d ago | $-0.190 | -0.010 |
| 90d ago | $-0.290 | +0.090 |
1 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 11, 2026 | LUCID CAPITAL MARKETS | UPGRADE | Neutral | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| May 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Apr 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 2 | 6 | 2 | 0 | 0 | 80% | |
| Feb 1, 2026 | 2 | 6 | 2 | 0 | 0 | 80% | |
| Jan 1, 2026 | 2 | 6 | 2 | 0 | 0 | 80% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 2, 2026
other
INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial
<p align="center"><i>XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad
May 20, 2026
Clinical Trial
INB03 for the Treatment of Pulmonary Complications From COVID-19
Phase Phase 3 — TERMINATED
May 15, 2026
other
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform
<p><strong>Boca Raton, FL, May 15, 2026 (GLOBE NEWSWIRE) -- </strong> INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company develop
May 14, 2026
other
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease
<p align="justify"><strong>BOCA RATON, FL, May 14, 2026 (GLOBE NEWSWIRE) -- </strong> INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology com
May 7, 2026
earnings
INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update
Company to Host Conference Call Today, May 7th, at 4:30pm ET <pre>Company to Host Conference Call Today, May 7th, at 4:30pm ET</pre>
May 7, 2026
earnings_calendar
INMB Q1 2026 Earnings Scheduled — 2026-05-07
May 6, 2026
earnings_calendar
INMB Q1 2026 Earnings Scheduled — 2026-05-06
May 5, 2026
announcement
INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases
<p><b>LONDON, UK and BOCA RATON, FL, May 05, 2026 (GLOBE NEWSWIRE) -- </b> INmune Bio Inc. (NASDAQ: INMB) (“INmune Bio”), a clinical-stage biotechno
Apr 30, 2026
earnings
INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th
<p><em>Management to host conference call and webcast at 4:30 pm ET on that day</em></p>
Apr 1, 2026
Clinical Trial
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
Phase Phase 2 — COMPLETED
Mar 30, 2026
earnings
INmune Bio Inc. Announces 2025 Results and Provides Business Update
Company to Host Conference Call Today, March 30, at 4:30pm ET <pre>Company to Host Conference Call Today, March 30, at 4:30pm ET</pre>
Mar 30, 2026
earnings_calendar
INMB Q4 2025 Earnings After Market Close — 2026-03-30
Mar 29, 2026
Clinical Trial
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
Phase Phase 2 — TERMINATED
Mar 25, 2026
earnings_calendar
INMB Q4 2025 Earnings After Market Close — 2026-03-25
Mar 19, 2026
announcement
INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease
<p align="center"><i>Plenary Presentation Highlights How Aligning Inflammatory Biomarker Enrichment with Mechanism of Action Offers a Blueprint for Su
Feb 26, 2026
earnings_calendar
INMB Q4 2025 Earnings After Market Close — 2026-02-26